PDCD1 and cancer: ICB therapies enhance the immune system’s ability to fight cancer by targeting immune-regulatory pathways, including programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [1].